speb/financial-data huggingface dataset:
BIO.B income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -341900000.00
BIO.B income_statement (quarterly, 2025-09-30) — Net Interest Income: 1400000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: -9500000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: 0.00
BIO.B cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: 0.00
BIO.B income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 1400000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -2500000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Net PPE: 720500000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -31700000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 5769700000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 872600000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 872600000.00
BIO.B income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 122800000.00
BIO.B income_statement (quarterly, 2025-09-30) — Normalized Income: 52581697.98
BIO.B cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 120900000.00
BIO.B income_statement (quarterly, 2025-09-30) — Operating Income: 63900000.00
BIO.B income_statement (quarterly, 2025-09-30) — Operating Revenue: 653000000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 26974126.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 23500000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Other Current Borrowings: 1300000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 127800000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: -166800000.00
BIO.B income_statement (quarterly, 2025-09-30) — Other Income Expense: -496400000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 388400000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Other Investments: 5057800000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 3400000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 109000000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 207500000.00
BIO.B income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 1000000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Other Properties: 720500000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 1022800000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Payables: 173600000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 356400000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Preferred Stock: 0.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 152000000.00
BIO.B income_statement (quarterly, 2025-09-30) — Pretax Income: -431100000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 3400000.00
BIO.B income_statement (quarterly, 2025-09-30) — Provision For Doubtful Accounts: 1400000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Purchase Of Business: -1800000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -223900000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -31700000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Raw Materials: 223900000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Receivables: 464700000.00
BIO.B income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 309600000.00
BIO.B income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 44200000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: 0.00
BIO.B cash_flow (quarterly, 2025-09-30) — Repurchase Of Capital Stock: -53400000.00
BIO.B income_statement (quarterly, 2025-09-30) — Research And Development: 71300000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Retained Earnings: 7456300000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 214400000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Sale Of PPE: 0.00
BIO.B income_statement (quarterly, 2025-09-30) — Selling General And Administration: 206800000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Share Issued: 30265870.00
BIO.B income_statement (quarterly, 2025-09-30) — Special Income Charges: -6000000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 14900000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 6736800000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 5769700000.00
BIO.B income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: -102918302.02
BIO.B income_statement (quarterly, 2025-09-30) — Tax Provision: -89200000.00
BIO.B income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.21
BIO.B balance_sheet (quarterly, 2025-09-30) — Total Assets: 9696400000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 7938200000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Total Debt: 1395300000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 6736800000.00
BIO.B income_statement (quarterly, 2025-09-30) — Total Expenses: 589100000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 2959600000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 6854400000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 2437300000.00
BIO.B income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: 65300000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 44800000.00
BIO.B income_statement (quarterly, 2025-09-30) — Total Unusual Items: -497400000.00
BIO.B income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: -497400000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Treasury Shares Number: 3291744.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Treasury Stock: 1014600000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Unrealized Gain Loss On Investment Securities: 495300000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Work In Process: 249800000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Working Capital: 2319700000.00
BIO.B income_statement (quarterly, 2025-09-30) — Write Off: 6000000.00
BIO.B income_statement (annual, 2025-12-31) — +Operating Expense: 1121300000.00
BIO.B income_statement (quarterly, 2025-12-31) — +Operating Expense: 291300000.00
BIO.B income_statement (annual, 2025-12-31) — +Total Revenue: 2583200000.00
BIO.B income_statement (quarterly, 2025-12-31) — +Total Revenue: 693200000.00
BIO.B balance_sheet (annual, 2025-12-31) — Accounts Payable: 129000000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 129000000.00
BIO.B balance_sheet (annual, 2025-12-31) — Accounts Receivable: 460600000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 460600000.00
BIO.B balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -1261000000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -1261000000.00
BIO.B balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 476000000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 476000000.00
BIO.B balance_sheet (annual, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -5500000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -5500000.00
BIO.B cash_flow (annual, 2025-12-31) — Asset Impairment Charge: 178800000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Asset Impairment Charge: 172800000.00
BIO.B income_statement (annual, 2025-12-31) — Basic Average Shares: 27263000.00
BIO.B income_statement (quarterly, 2025-12-31) — Basic Average Shares: 26976000.00
BIO.B income_statement (annual, 2025-12-31) — Basic EPS: 27.87
BIO.B income_statement (quarterly, 2025-12-31) — Basic EPS: 26.69
BIO.B cash_flow (annual, 2025-12-31) — Beginning Cash Position: 489800000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 398200000.00
BIO.B balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 449400000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 449400000.00
BIO.B cash_flow (annual, 2025-12-31) — Capital Expenditure: -157600000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -45800000.00
BIO.B balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 181800000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 181800000.00
BIO.B balance_sheet (annual, 2025-12-31) — Capital Stock: 0.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Capital Stock: 0.00
BIO.B balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 529800000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 529800000.00
BIO.B balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 1540700000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 1540700000.00
BIO.B cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: -283200000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 3300000.00
BIO.B cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -189700000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -34200000.00
BIO.B cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 532200000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 164900000.00
BIO.B cash_flow (annual, 2025-12-31) — Change In Account Payable: -100000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Change In Account Payable: -1300000.00
BIO.B cash_flow (annual, 2025-12-31) — Change In Income Tax Payable: 1500000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Change In Income Tax Payable: 13600000.00
BIO.B cash_flow (annual, 2025-12-31) — Change In Inventory: 68900000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Change In Inventory: 51600000.00
BIO.B cash_flow (annual, 2025-12-31) — Change In Other Current Assets: 12200000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Change In Other Current Assets: -4200000.00
BIO.B cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: -200000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: 300000.00
BIO.B cash_flow (annual, 2025-12-31) — Change In Other Working Capital: 170500000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: 190200000.00
BIO.B cash_flow (annual, 2025-12-31) — Change In Payable: 1400000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Change In Payable: 12300000.00
BIO.B cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 1400000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 12300000.00
BIO.B cash_flow (annual, 2025-12-31) — Change In Receivables: 19600000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Change In Receivables: 3900000.00
BIO.B cash_flow (annual, 2025-12-31) — Change In Tax Payable: 1500000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Change In Tax Payable: 13600000.00
BIO.B cash_flow (annual, 2025-12-31) — Change In Working Capital: 272400000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 254100000.00
BIO.B cash_flow (annual, 2025-12-31) — Changes In Account Receivables: 19600000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: 3900000.00
BIO.B cash_flow (annual, 2025-12-31) — Changes In Cash: 59300000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Changes In Cash: 134000000.00
BIO.B balance_sheet (annual, 2025-12-31) — Common Stock: 0.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Common Stock: 0.00
BIO.B balance_sheet (annual, 2025-12-31) — Common Stock Equity: 7453600000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 7453600000.00
BIO.B cash_flow (annual, 2025-12-31) — Common Stock Payments: -295500000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Common Stock Payments: 0.00
BIO.B income_statement (annual, 2025-12-31) — Cost Of Revenue: 1243300000.00
BIO.B income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 348000000.00
BIO.B balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 172300000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 172300000.00
BIO.B balance_sheet (annual, 2025-12-31) — Current Assets: 2906200000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Current Assets: 2906200000.00
BIO.B balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 36100000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 36100000.00
BIO.B balance_sheet (annual, 2025-12-31) — Current Debt: 1300000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Current Debt: 1300000.00
BIO.B balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 37400000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 37400000.00
BIO.B balance_sheet (annual, 2025-12-31) — Current Liabilities: 517000000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 517000000.00
BIO.B cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 165400000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 42500000.00
BIO.B cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 165400000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 42500000.00
BIO.B income_statement (annual, 2025-12-31) — Diluted Average Shares: 27281000.00
BIO.B income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 27012000.00
BIO.B income_statement (annual, 2025-12-31) — Diluted EPS: 27.85
BIO.B income_statement (quarterly, 2025-12-31) — Diluted EPS: 26.65
BIO.B income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: 759900000.00
BIO.B income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 720000000.00
BIO.B income_statement (annual, 2025-12-31) — EBIT: 1044500000.00
BIO.B income_statement (quarterly, 2025-12-31) — EBIT: 941300000.00
BIO.B income_statement (annual, 2025-12-31) — EBITDA: 1209900000.00
BIO.B income_statement (quarterly, 2025-12-31) — EBITDA: 983800000.00
BIO.B cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: -16900000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: 0.00
BIO.B cash_flow (annual, 2025-12-31) — End Cash Position: 532200000.00
BIO.B cash_flow (quarterly, 2025-12-31) — End Cash Position: 532200000.00
BIO.B cash_flow (annual, 2025-12-31) — Financing Cash Flow: -283200000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 3300000.00
BIO.B balance_sheet (annual, 2025-12-31) — Finished Goods: 293300000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Finished Goods: 293300000.00
BIO.B cash_flow (annual, 2025-12-31) — Free Cash Flow: 374600000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 119100000.00
BIO.B cash_flow (annual, 2025-12-31) — Gain Loss On Sale Of Business: 0.00
BIO.B income_statement (annual, 2025-12-31) — Gain On Sale Of Security: 908000000.00
BIO.B income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: 1030200000.00
BIO.B balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -189100000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -189100000.00
BIO.B balance_sheet (annual, 2025-12-31) — Goodwill: 579800000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Goodwill: 579800000.00
BIO.B balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 754100000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 754100000.00
BIO.B balance_sheet (annual, 2025-12-31) — Gross Accounts Receivable: 466100000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Gross Accounts Receivable: 466100000.00
BIO.B balance_sheet (annual, 2025-12-31) — Gross PPE: 1970900000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Gross PPE: 1970900000.00
BIO.B income_statement (annual, 2025-12-31) — Gross Profit: 1339900000.00
BIO.B income_statement (quarterly, 2025-12-31) — Gross Profit: 345200000.00
BIO.B income_statement (annual, 2025-12-31) — Impairment Of Capital Assets: 172800000.00
BIO.B income_statement (annual, 2025-12-31) — Interest Expense: 49000000.00
BIO.B income_statement (quarterly, 2025-12-31) — Interest Expense: 12100000.00
BIO.B income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 49000000.00
BIO.B income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 12100000.00
BIO.B income_statement (annual, 2025-12-31) — Interest Income: 95500000.00
BIO.B income_statement (quarterly, 2025-12-31) — Interest Income: 31000000.00
BIO.B income_statement (annual, 2025-12-31) — Interest Income Non Operating: 95500000.00
BIO.B income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 31000000.00
BIO.B balance_sheet (annual, 2025-12-31) — Inventory: 740700000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Inventory: 740700000.00
BIO.B balance_sheet (annual, 2025-12-31) — Invested Capital: 8657900000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Invested Capital: 8657900000.00
BIO.B cash_flow (annual, 2025-12-31) — Investing Cash Flow: -189700000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -34200000.00
BIO.B balance_sheet (annual, 2025-12-31) — Investments And Advances: 6103600000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 6103600000.00
BIO.B balance_sheet (annual, 2025-12-31) — Land And Improvements: 28900000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Land And Improvements: 28900000.00
BIO.B balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 145700000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 145700000.00
BIO.B balance_sheet (annual, 2025-12-31) — Long Term Debt: 1203000000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 1203000000.00
BIO.B balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 1348700000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 1348700000.00
BIO.B cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -500000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: -200000.00
BIO.B cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: -218500000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: 0.00
BIO.B cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: -295500000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 0.00
BIO.B balance_sheet (annual, 2025-12-31) — Net Debt: 674500000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Net Debt: 674500000.00
BIO.B income_statement (annual, 2025-12-31) — Net Income: 759900000.00
BIO.B income_statement (quarterly, 2025-12-31) — Net Income: 720000000.00
BIO.B income_statement (annual, 2025-12-31) — Net Income Common Stockholders: 759900000.00
BIO.B income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 720000000.00
BIO.B income_statement (annual, 2025-12-31) — Net Income Continuous Operations: 759900000.00
BIO.B income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 720000000.00
BIO.B income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 759900000.00
BIO.B income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 720000000.00
BIO.B income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 759900000.00
BIO.B income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 720000000.00
BIO.B cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: 759900000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: 720000000.00
BIO.B income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: 759900000.00
BIO.B income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 720000000.00
BIO.B cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: 0.00
BIO.B cash_flow (quarterly, 2025-12-31) — Net Intangibles Purchase And Sale: 0.00
BIO.B income_statement (annual, 2025-12-31) — Net Interest Income: 46500000.00
BIO.B income_statement (quarterly, 2025-12-31) — Net Interest Income: 18900000.00
BIO.B cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: 186300000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: 11600000.00
BIO.B cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -500000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -200000.00
BIO.B cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -500000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -200000.00
BIO.B income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 46500000.00
BIO.B income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 18900000.00
BIO.B cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -3000000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -400000.00
BIO.B balance_sheet (annual, 2025-12-31) — Net PPE: 709900000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Net PPE: 709900000.00
BIO.B cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -157500000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -45800000.00
BIO.B balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 6699500000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 6699500000.00
BIO.B balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 1059400000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 1059400000.00
BIO.B balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 1059400000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 1059400000.00
BIO.B income_statement (annual, 2025-12-31) — Normalized EBITDA: 480700000.00
BIO.B income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 126400000.00
BIO.B income_statement (annual, 2025-12-31) — Normalized Income: 203276112.51
BIO.B income_statement (quarterly, 2025-12-31) — Normalized Income: 55634954.80
BIO.B cash_flow (annual, 2025-12-31) — Operating Cash Flow: 532200000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 164900000.00
BIO.B income_statement (annual, 2025-12-31) — Operating Income: 218600000.00
BIO.B income_statement (quarterly, 2025-12-31) — Operating Income: 53900000.00
BIO.B income_statement (annual, 2025-12-31) — Operating Revenue: 2583200000.00
BIO.B income_statement (quarterly, 2025-12-31) — Operating Revenue: 693200000.00
BIO.B balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 26990394.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 26990394.00
BIO.B balance_sheet (annual, 2025-12-31) — Other Current Assets: 27700000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 27700000.00
BIO.B balance_sheet (annual, 2025-12-31) — Other Current Borrowings: 1300000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Other Current Borrowings: 1300000.00
BIO.B balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 141700000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 141700000.00
BIO.B balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: -189100000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: -189100000.00
BIO.B income_statement (annual, 2025-12-31) — Other Income Expense: 730400000.00
BIO.B income_statement (quarterly, 2025-12-31) — Other Income Expense: 856400000.00
BIO.B balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 174300000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 174300000.00
BIO.B balance_sheet (annual, 2025-12-31) — Other Investments: 6103600000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Other Investments: 6103600000.00
BIO.B cash_flow (annual, 2025-12-31) — Other Non Cash Items: -3300000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: -10900000.00
BIO.B balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 102700000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 102700000.00
BIO.B balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 197800000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 197800000.00
BIO.B income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 1200000.00
BIO.B income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: -1000000.00
BIO.B balance_sheet (annual, 2025-12-31) — Other Properties: 1492600000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Other Properties: 1492600000.00
BIO.B balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 1010900000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 1010900000.00
BIO.B balance_sheet (annual, 2025-12-31) — Payables: 165600000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Payables: 165600000.00
BIO.B balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 337900000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 337900000.00
BIO.B balance_sheet (annual, 2025-12-31) — Preferred Stock: 0.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Preferred Stock: 0.00
BIO.B balance_sheet (annual, 2025-12-31) — Prepaid Assets: 136500000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 136500000.00
BIO.B income_statement (annual, 2025-12-31) — Pretax Income: 995500000.00
BIO.B income_statement (quarterly, 2025-12-31) — Pretax Income: 929200000.00
BIO.B cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 15800000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 3900000.00
BIO.B balance_sheet (annual, 2025-12-31) — Properties: 0.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
BIO.B income_statement (annual, 2025-12-31) — Provision For Doubtful Accounts: 1400000.00
BIO.B income_statement (quarterly, 2025-12-31) — Provision For Doubtful Accounts: 0.00
BIO.B cash_flow (annual, 2025-12-31) — Provisionand Write Offof Assets: 1400000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Provisionand Write Offof Assets: 0.00
BIO.B cash_flow (annual, 2025-12-31) — Purchase Of Business: -218500000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Purchase Of Business: 0.00
BIO.B cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: 0.00
BIO.B cash_flow (quarterly, 2025-12-31) — Purchase Of Intangibles: 0.00
BIO.B cash_flow (annual, 2025-12-31) — Purchase Of Investment: -669300000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -138800000.00
BIO.B cash_flow (annual, 2025-12-31) — Purchase Of PPE: -157600000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -45800000.00
BIO.B balance_sheet (annual, 2025-12-31) — Raw Materials: 212500000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Raw Materials: 212500000.00
BIO.B balance_sheet (annual, 2025-12-31) — Receivables: 460600000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Receivables: 460600000.00
BIO.B income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 1243300000.00
BIO.B income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 348000000.00
BIO.B income_statement (annual, 2025-12-31) — Reconciled Depreciation: 165400000.00
BIO.B income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 42500000.00
BIO.B cash_flow (annual, 2025-12-31) — Repayment Of Debt: -500000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -200000.00
BIO.B cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: -295500000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Repurchase Of Capital Stock: 0.00
BIO.B income_statement (annual, 2025-12-31) — Research And Development: 275600000.00
BIO.B income_statement (quarterly, 2025-12-31) — Research And Development: 70300000.00
BIO.B balance_sheet (annual, 2025-12-31) — Retained Earnings: 8176300000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Retained Earnings: 8176300000.00
BIO.B cash_flow (annual, 2025-12-31) — Sale Of Business: 0.00
BIO.B cash_flow (annual, 2025-12-31) — Sale Of Investment: 855600000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 150400000.00
BIO.B cash_flow (annual, 2025-12-31) — Sale Of PPE: 100000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Sale Of PPE: 0.00
BIO.B income_statement (annual, 2025-12-31) — Selling General And Administration: 844300000.00
BIO.B income_statement (quarterly, 2025-12-31) — Selling General And Administration: 221000000.00
BIO.B balance_sheet (annual, 2025-12-31) — Share Issued: 30265870.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Share Issued: 30265870.00
BIO.B income_statement (annual, 2025-12-31) — Special Income Charges: -178800000.00
BIO.B income_statement (quarterly, 2025-12-31) — Special Income Charges: -172800000.00
BIO.B cash_flow (annual, 2025-12-31) — Stock Based Compensation: 58000000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 15900000.00
BIO.B balance_sheet (annual, 2025-12-31) — Stockholders Equity: 7453600000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 7453600000.00
BIO.B balance_sheet (annual, 2025-12-31) — Tangible Book Value: 6699500000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 6699500000.00
BIO.B income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 172576112.51
BIO.B income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 193034954.80
BIO.B income_statement (annual, 2025-12-31) — Tax Provision: 235600000.00
BIO.B income_statement (quarterly, 2025-12-31) — Tax Provision: 209200000.00
BIO.B income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.24
BIO.B income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.23
BIO.B balance_sheet (annual, 2025-12-31) — Total Assets: 10576500000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Total Assets: 10576500000.00
BIO.B balance_sheet (annual, 2025-12-31) — Total Capitalization: 8656600000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 8656600000.00
BIO.B balance_sheet (annual, 2025-12-31) — Total Debt: 1386100000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Total Debt: 1386100000.00
BIO.B balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 7453600000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 7453600000.00
BIO.B income_statement (annual, 2025-12-31) — Total Expenses: 2364600000.00
BIO.B income_statement (quarterly, 2025-12-31) — Total Expenses: 639300000.00
BIO.B balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 3122900000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 3122900000.00
BIO.B balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 7670300000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 7670300000.00
BIO.B balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 2605900000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 2605900000.00
BIO.B income_statement (annual, 2025-12-31) — Total Operating Income As Reported: 47200000.00
BIO.B income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -118900000.00
BIO.B balance_sheet (annual, 2025-12-31) — Total Tax Payable: 36600000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 36600000.00
BIO.B income_statement (annual, 2025-12-31) — Total Unusual Items: 729200000.00
BIO.B income_statement (quarterly, 2025-12-31) — Total Unusual Items: 857400000.00
BIO.B income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: 729200000.00
BIO.B income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 857400000.00
BIO.B balance_sheet (annual, 2025-12-31) — Treasury Shares Number: 3275476.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Treasury Shares Number: 3275476.00
BIO.B balance_sheet (annual, 2025-12-31) — Treasury Stock: 1009600000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Treasury Stock: 1009600000.00
BIO.B cash_flow (annual, 2025-12-31) — Unrealized Gain Loss On Investment Securities: -900400000.00
BIO.B cash_flow (quarterly, 2025-12-31) — Unrealized Gain Loss On Investment Securities: -1029500000.00
BIO.B balance_sheet (annual, 2025-12-31) — Work In Process: 234900000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Work In Process: 234900000.00
BIO.B balance_sheet (annual, 2025-12-31) — Working Capital: 2389200000.00
BIO.B balance_sheet (quarterly, 2025-12-31) — Working Capital: 2389200000.00
BIO.B income_statement (annual, 2025-12-31) — Write Off: 6000000.00
BIO.B income_statement (quarterly, 2025-12-31) — Write Off: 0.00
BIO.B income_statement (quarterly, 2026-03-31) — +Operating Expense: 275300000.00
BIO.B income_statement (quarterly, 2026-03-31) — +Total Revenue: 592100000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 133100000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 426200000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 490500000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -4900000.00
BIO.B income_statement (quarterly, 2026-03-31) — Basic Average Shares: 26958000.00
BIO.B income_statement (quarterly, 2026-03-31) — Basic EPS: -19.55
BIO.B cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 532200000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -30000000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 174800000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Capital Stock: 0.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 507200000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 1564700000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: -44000000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -93200000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: 108100000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Change In Account Payable: 9600000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Change In Income Tax Payable: -10200000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Change In Inventory: -29900000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Change In Other Current Assets: -4800000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Change In Other Current Liabilities: 2000000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: -166000000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Change In Payable: -600000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -600000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Change In Receivables: 30800000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Change In Tax Payable: -10200000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -168500000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: 30800000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Changes In Cash: -29100000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Common Stock: 0.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 6851300000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Common Stock Payments: -47800000.00
BIO.B income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 282700000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 148400000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Current Assets: 2942100000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 36200000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Current Debt: 400500000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 436700000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 917000000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 40900000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 40900000.00
BIO.B income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 26958000.00
BIO.B income_statement (quarterly, 2026-03-31) — Diluted EPS: -19.55
BIO.B income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -527100000.00
BIO.B income_statement (quarterly, 2026-03-31) — EBIT: -677500000.00
BIO.B income_statement (quarterly, 2026-03-31) — EBITDA: -636600000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: 5900000.00
BIO.B cash_flow (quarterly, 2026-03-31) — End Cash Position: 509000000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: -44000000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Finished Goods: 330300000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Free Cash Flow: 78100000.00
BIO.B income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: -733300000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: -235400000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Goodwill: 577100000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 743900000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 431100000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Gross PPE: 689400000.00
BIO.B income_statement (quarterly, 2026-03-31) — Gross Profit: 309400000.00
BIO.B income_statement (quarterly, 2026-03-31) — Interest Expense: 12300000.00
BIO.B income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 12300000.00
BIO.B income_statement (quarterly, 2026-03-31) — Interest Income: 21000000.00
BIO.B income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 21000000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Inventory: 770500000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Invested Capital: 8054700000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -93200000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 5311800000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 138600000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 802900000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 941500000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -100000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: -47800000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Net Debt: 696200000.00
BIO.B income_statement (quarterly, 2026-03-31) — Net Income: -527100000.00
BIO.B income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -527100000.00
BIO.B income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -527100000.00
BIO.B income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -527100000.00
BIO.B income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -527100000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -527100000.00
BIO.B income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -527100000.00
BIO.B income_statement (quarterly, 2026-03-31) — Net Interest Income: 8700000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: -63300000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -100000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -100000.00
BIO.B income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 8700000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Net PPE: 689400000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -29900000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 6107400000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 881800000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 881800000.00
BIO.B income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 96700000.00
BIO.B income_statement (quarterly, 2026-03-31) — Normalized Income: 33239852.13
BIO.B cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: 108100000.00
BIO.B income_statement (quarterly, 2026-03-31) — Operating Income: 34100000.00
BIO.B income_statement (quarterly, 2026-03-31) — Operating Revenue: 592100000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 26828488.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 30700000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Other Current Borrowings: 400500000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 153900000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: -235400000.00
BIO.B income_statement (quarterly, 2026-03-31) — Other Income Expense: -732600000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 166800000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Other Investments: 5311800000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 9600000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 102800000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 198400000.00
BIO.B income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 700000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Other Properties: 689400000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 1057500000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Payables: 178000000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 326400000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 0.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 150000000.00
BIO.B income_statement (quarterly, 2026-03-31) — Pretax Income: -689800000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 3900000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: -226100000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -30000000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Raw Materials: 214700000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Receivables: 426200000.00
BIO.B income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 282700000.00
BIO.B income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 40900000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -100000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Repurchase Of Capital Stock: -47800000.00
BIO.B income_statement (quarterly, 2026-03-31) — Research And Development: 62900000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 7649200000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 162800000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Sale Of PPE: 100000.00
BIO.B income_statement (quarterly, 2026-03-31) — Selling General And Administration: 212400000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Share Issued: 30265870.00
BIO.B cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 15000000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 6851300000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 6107400000.00
BIO.B income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -172960147.87
BIO.B income_statement (quarterly, 2026-03-31) — Tax Provision: -162700000.00
BIO.B income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.24
BIO.B balance_sheet (quarterly, 2026-03-31) — Total Assets: 9790000000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 7654200000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Total Debt: 1378200000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 6851300000.00
BIO.B income_statement (quarterly, 2026-03-31) — Total Expenses: 558000000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 2938700000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 6847900000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 2021700000.00
BIO.B income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: 34100000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 44900000.00
BIO.B income_statement (quarterly, 2026-03-31) — Total Unusual Items: -733300000.00
BIO.B income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -733300000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 3437382.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Treasury Stock: 1053000000.00
BIO.B cash_flow (quarterly, 2026-03-31) — Unrealized Gain Loss On Investment Securities: 738200000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Work In Process: 225500000.00
BIO.B balance_sheet (quarterly, 2026-03-31) — Working Capital: 2025100000.00
BIOA income_statement (annual, 2022-12-31) — +Operating Expense: 39969000.00
BIOA income_statement (annual, 2022-12-31) — +Total Revenue: 0.00
BIOA balance_sheet (annual, 2022-12-31) — Accounts Payable: 2261000.00
BIOA balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -253000.00
BIOA balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 5122000.00
BIOA income_statement (annual, 2022-12-31) — Basic Average Shares: 1671761.00
BIOA income_statement (annual, 2022-12-31) — Basic EPS: -23.76
BIOA cash_flow (annual, 2022-12-31) — Beginning Cash Position: 61183000.00
BIOA cash_flow (annual, 2022-12-31) — Capital Expenditure: -103000.00
BIOA balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 49000.00
BIOA balance_sheet (annual, 2022-12-31) — Capital Stock: 0.00
BIOA balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 27644000.00
BIOA balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 27644000.00
BIOA cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 2499000.00
BIOA cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -103000.00
BIOA cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -36181000.00
BIOA cash_flow (annual, 2022-12-31) — Change In Account Payable: 994000.00
BIOA cash_flow (annual, 2022-12-31) — Change In Accrued Expense: -521000.00
BIOA cash_flow (annual, 2022-12-31) — Change In Other Current Assets: 352000.00
BIOA cash_flow (annual, 2022-12-31) — Change In Payable: 994000.00
BIOA cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: 473000.00
BIOA cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: -30000.00
BIOA cash_flow (annual, 2022-12-31) — Change In Working Capital: 795000.00
BIOA cash_flow (annual, 2022-12-31) — Changes In Cash: -33785000.00
BIOA balance_sheet (annual, 2022-12-31) — Common Stock: 0.00
BIOA balance_sheet (annual, 2022-12-31) — Common Stock Equity: -112559000.00
BIOA balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 3360000.00
BIOA balance_sheet (annual, 2022-12-31) — Current Assets: 28030000.00
BIOA balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 49000.00
BIOA balance_sheet (annual, 2022-12-31) — Current Debt: 167000.00
BIOA balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 216000.00